Yahoo Finance

BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®

NEW YORK, June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival ...
Nasdaq

BrainStorm Announces NurOwn® Expanded Access Program

NurOwn® will be made available for ALS patients who completed all Phase 3 clinical trial assessments and meet specific eligibility criteria NEW YORK, Dec. 14, 2020 /PRNewswire/ -- BrainStorm Cell ...
Nasdaq

BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting

NEW YORK, Oct. 28, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of ...
Seeking Alpha

Brainstorm Cell Therapeutics Inc. (BCLI) Corporate Mid-Year Update on NurOwn Program (Transcript)

Greetings and welcome to the Brainstorm Cell Therapeutics Mid-Year 2024 Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded. And I ...
ascopubs.org

BrainStorm: A brain metastases research platform to tackle the challenge of central nervous system (CNS) metastases in solid tumors (Oncodistinct 006).

LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma. Background: Better knowledge on the evolving epidemiology and biology of CNS metastases are key elements for the ...
Scoop

ParaMind Brainstorming Software releases New Ver.

ParaMind Brainstorming Software releases New Version of its Unique Brainstorming Software Program. ParaMind Brainstorming Software of Seattle, Washington announces the release of their new advanced ...